Skip to main content

Jazz buys Virginia biotech firm in deal valued at up to $312.5M

The company Jazz bought is developing a new treatment for a a nervous system disorder that causes rhythmic shaking.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.